# leon-nanodrugs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leon-nanodrugs

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.leon-nanodrugs.com
- Total disclosed funding: $21M
- Latest round: Series D (Aug 6, 2024)
- Investors on record: 10

## About

Leon Nanodrugs is a biopharmaceutical company specializing in advanced manufacturing solutions for nanoparticle-based drug delivery systems, focusing on improving therapeutic substance delivery.Founded in 2011, Leon Nanodrugs GmbH, headquartered in Munich, Germany, is engaged in developing innovative nanocarrier manufacturing technologies.In March 2026, leon-nanodrugs GmbH raised an undisclosed amount of venture funding from unspecified investors.The CEO, Hans Frickel, has been pivotal in the company's strategic direction since its inception by founders Cornelia Beier and Wolfgang Beier.Leon Nanodrugs focuses on advanced manufacturing solutions for nanocarrier production, primarily utilizing their proprietary FR-JET technology. This technology enables the creation of homogeneous nanoparticle-based drug delivery systems, which serve as carrier vehicles for the protection and targeted delivery of therapeutic substances including genetic material, RNA, and small molecules. The systems are designed for both small-scale personalized medicine and larger commercial batch production, thereby addressing the diverse needs of pharmaceutical, biotechnology, and Contract Development and Manufacturing Organizations (CDMOs). Leon Nanodrugs' products are marketed to clients in Europe, North America, and Asia, facilitating improved drug stability, solubility, and bioavailability, ultimately enhancing the availability of personalized medicine to a global audience.Leon Nanodrugs operates on a B2B model, directly engaging with pharmaceutical companies, biotech firms, and CDMOs to provide advanced manufacturing solutions. Revenue is generated through the sale of specialized equipment and technology, particularly the FR-JET systems, which are flagship products within their portfolio. These products are typically sold with tailored service agreements that may include installation, training, and ongoing technical support. The pricing structure reflects the high-value nature of the technology, often involving structured procurement processes based on specific client needs and production capacities, and promoting long-term partnerships.The company will use the March 2026 funding to support the market launch of its NANO systems and drive global commercial expansion to meet growing demand from pharmaceutical and biotechnology companies for scalable nanoparticle manufacturing.

## Funding rounds

- Series D, Aug 6, 2024 — TVM Capital Life Science, LBBW Venture Capital, Signet Healthcare Partners, CD-Venture, Eckenstein-Geigy-Stiftung, Albany Private Equity Partners
- Series B, Apr 16, 2020 — TVM Capital Life Science, Evotec SE, BayBG, CD-Venture, Eckenstein-Geigy-Stiftung, Albany Private Equity Partners, LOF Leon Partnership
- Series A, Jun 10, 2015, $21M — TVM Capital Life Science, CD-Venture, Eckenstein-Geigy-Stiftung, Albany Private Equity Holding

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B, Series D
- CD-Venture (https://capitalatlas.ai/funds/cd-venture) — Series A, Series B, Series D
- Eckenstein-Geigy-Stiftung — Series A, Series B, Series D
- Albany Private Equity Holding — Series A
- Evotec SE — Series B
- BayBG (https://capitalatlas.ai/funds/baybg) — Series B
- Albany Private Equity Partners — Series B, Series D
- LOF Leon Partnership — Series B
- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Series D
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series D